In December 2004, Philip Morabito sued Pfizer and Henry A. McKinnell, then Pfizer's board chair and chief executive officer, alleging two claims under the Securities and Exchange Act of 1934. In 2012, an amended complaint was filed that alleged that Pfizer and the individual defendants had made false representations and omissions regarding the cardiovascular risks associated with two of Pfizer's drugs: Celebrex and Bextra. (Photo: Daniel Acker/Bloomberg)
A Delaware court has ruled that exclusions in insurance policies issued to Pfizer Inc. did not preclude coverage for the $568 million it agreed to pay to settle a securities fraud class action.
|The case
In December 2004, Philip Morabito sued Pfizer and Henry A. McKinnell, then Pfizer's board chair and chief executive officer, on behalf of those who purchased Pfizer's common stock between November 1, 2000 and December 16, 2004 (class period). The suit alleged two claims under the Securities and Exchange Act of 1934: violations of Section 10(b) and Section 20(a) of the 1934 Act and the rules promulgated thereunder.
Recommended For You
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.